Literature DB >> 28087270

Examining the reliability and validity of the Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study.

Jack J Blanchard1, Kristen R Bradshaw2, Cristina P Garcia2, Henry A Nasrallah3, Philip D Harvey4, Daniel Casey5, Csilla T Csoboth6, James I Hudson7, Laura Julian6, Ellen Lentz6, Keith H Nuechterlein8, Diana O Perkins9, Tracey G Skale10, Lonnie R Snowden11, Rajiv Tandon12, Cenk Tek13, Dawn Velligan14, Sophia Vinogradov15, Cedric O'Gorman16.   

Abstract

The current study sought to expand on prior reports of the validity and reliability of the CAINS (CAINS) by examining its performance across diverse non-academic clinical settings as employed by raters not affiliated with the scale's developers and across a longer test-retest follow-up period. The properties of the CAINS were examined within the Management of Schizophrenia in Clinical Practice (MOSAIC) schizophrenia registry. A total of 501 participants with a schizophrenia spectrum diagnosis who were receiving usual care were recruited across 15 national Patient Assessment Centers and evaluated with the CAINS, other negative symptom measures, and assessments of functioning, quality of life and cognition. Temporal stability of negative symptoms was assessed across a 3-month follow-up. Results replicated the two-factor structure of the CAINS reflecting Motivation and Pleasure and expression symptoms. The CAINS scales exhibited high internal consistency and temporal stability. Convergent validity was supported by significant correlations between the CAINS subscales with other negative symptom measures. Additionally, the CAINS was significantly correlated with functioning and quality of life. Discriminant validity was demonstrated by small to moderate associations between the CAINS and positive symptoms, depression, and cognition (and these associations were comparable to those found with other negative symptom scales). Findings suggest that the CAINS is a reliable and valid tool for measuring negative symptoms in schizophrenia across diverse clinical samples and settings.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Assessment; Clinical interview; Functioning; Negative symptoms; Schizophrenia

Mesh:

Year:  2017        PMID: 28087270     DOI: 10.1016/j.schres.2017.01.011

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  8 in total

Review 1.  Primary, Enduring Negative Symptoms: An Update on Research.

Authors:  Brian Kirkpatrick; Armida Mucci; Silvana Galderisi
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

2.  Cognitive, community functioning and clinical correlates of the Clinical Assessment Interview for Negative Symptoms (CAINS) in psychotic disorders.

Authors:  Manuel J Cuesta; Ana M Sánchez-Torres; Ruth Lorente-Omeñaca; Lucía Moreno-Izco; Victor Peralta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-09-07       Impact factor: 5.270

3.  Sleep disturbance and sleep-related impairment in psychotic disorders are related to both positive and negative symptoms.

Authors:  Jack J Blanchard; Alexandra Andrea; Ryan D Orth; Christina Savage; Melanie E Bennett
Journal:  Psychiatry Res       Date:  2020-02-07       Impact factor: 3.222

4.  Cross Cultural Validation and Extension of the Clinical Assessment Interview for Negative Symptoms (CAINS) in the Chinese Context: Evidence from a Spectrum Perspective.

Authors:  Dong-Jie Xie; Hai-Song Shi; Simon S Y Lui; Chuan Shi; Ying Li; Karen K Y Ho; Karen S Y Hung; Wen-Xiu Li; Zheng-Hui Yi; Eric F C Cheung; Ann M Kring; Raymond C K Chan
Journal:  Schizophr Bull       Date:  2018-10-15       Impact factor: 9.306

5.  Pilot Validation Study of the Japanese Translation of the Brief Negative Symptoms Scale (BNSS).

Authors:  Naoki Hashimoto; Atsuhito Toyomaki; Matsuhiko Oka; Keisuke Takanobu; Ryo Okubo; Hisashi Narita; Kan Kitagawa; Niki Udo; Tamaki Maeda; Shinya Watanabe; Yuka Oyanagi; Akane Miyazaki; Koki Ito; Ichiro Kusumi
Journal:  Neuropsychiatr Dis Treat       Date:  2019-12-23       Impact factor: 2.570

6.  EPA guidance on assessment of negative symptoms in schizophrenia.

Authors:  S Galderisi; A Mucci; S Dollfus; M Nordentoft; P Falkai; S Kaiser; G M Giordano; A Vandevelde; M Ø Nielsen; L B Glenthøj; M Sabé; P Pezzella; I Bitter; W Gaebel
Journal:  Eur Psychiatry       Date:  2021-02-18       Impact factor: 5.361

7.  Sleep Problems and Social Impairment in Psychosis: A Transdiagnostic Study Examining Multiple Social Domains.

Authors:  Jack J Blanchard; Christina L G Savage; Ryan D Orth; Anyela M Jacome; Melanie E Bennett
Journal:  Front Psychiatry       Date:  2020-05-28       Impact factor: 4.157

Review 8.  [Differential diagnostic distinction between substance-induced and primary psychoses: : Recommendations for general psychiatric and forensic practice].

Authors:  Dusan Hirjak; Andreas Meyer-Lindenberg; Geva A Brandt; Harald Dreßing
Journal:  Nervenarzt       Date:  2021-03-03       Impact factor: 1.214

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.